MariTime CV
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants Living with Overweight or Obesity and Atherosclerotic Cardiovascular Disease
- Stadium
- inclusie
- Middel
- Meridebart Cafraglutide
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 15 oktober 2025
- Last Patient In
- 29 maart 2027
- Last Patient Last Visit
- 29 september 2030
Inclusieperiode, nog 485 dagen over
National Lead
prof. dr. J.H. Cornel
Cardioloog
Studiedirecteur
drs. H.P. Swart
Cardioloog
Contact Kantoor
